GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
Recruiting now
Conditions studied: Breast Cancer Invasive
In brief
To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response (pCR), aiming to provide a new and effective means for accurately and non-invasively evaluating the efficacy of neoadjuvant therapy.
Key facts
- Study ID
- NCT06725940
- Run by
- Shanghai Jiao Tong University School of Medicine
- People needed
- 50
- Starts
- 2024-11-01
- Expected to finish
- 2025-11-01
- Last updated by the study team
- 2024-12-10
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- age 16-65
- histologically confirmed unilateral primary invasive breast cancer
- Tumor size≥2cm, axillary lymph node positive, treated with neoadjuvant therapy
- complete clinical and histo-pathological information
- ECOG 0-1 within 10 days from the beginning of the study
- Normal Bone Marrow Reserve: White blood cell count ≥ 3.0×10\^9/L, Neutrophil count ≥ 1.5×10\^9/L, Hemoglobin level ≥ 90g/L; Platelet count (PLT) ≥ 80×10\^9/L; Normal Liver and Kidney Function: Blood aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal, Total bilirubin ≤ 1.5 times the upper limit of normal, Serum creatinine ≤ 1.5 times the upper limit of normal, and Creatinine clearance rate > 50ml/min.
- The patient has good compliance with the planned treatment, understands the research procedures, and has signed a written informed consent form
You may not qualify if…
- bilateral or metastatic (stage IV) breast cancer
- There has been a history of other malignancies within the past 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer
- Severe systemic infection or other uncontrolled diseases
- Patients with psychiatric disorders or those unable to comply with treatment due to other reasons
- Known allergy or intolerance to the drug or its excipients
- Having received cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiotherapy for any reason in the past
- Patients who are pregnant or lactating, as well as patients of reproductive age who refuse to take appropriate contraceptive measures during the course of this trial.
- Patients deemed unsuitable for participation in this study by the investigator.
Where it is running
- Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.